Plantarc Bio Ltd - Asset Resilience Ratio
Plantarc Bio Ltd (PLNT) has an Asset Resilience Ratio of 34.61% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Plantarc Bio Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2023)
This chart shows how Plantarc Bio Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PLNT total asset value.
Liquid Assets Composition Over Time
This chart breaks down Plantarc Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PLNT total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA4.07 Million | 34.61% |
| Total Liquid Assets | ILA4.07 Million | 34.61% |
Asset Resilience Insights
- Very High Liquidity: Plantarc Bio Ltd maintains exceptional liquid asset reserves at 34.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Plantarc Bio Ltd Industry Peers by Asset Resilience Ratio
Compare Plantarc Bio Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS |
Biotechnology | 20.92% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Mesoblast Ltd
AU:MSB |
Biotechnology | 0.00% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
Annual Asset Resilience Ratio for Plantarc Bio Ltd (2022–2023)
The table below shows the annual Asset Resilience Ratio data for Plantarc Bio Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 63.07% | ILA8.32 Million ≈ $22.30K |
ILA13.19 Million ≈ $35.35K |
+10.24pp |
| 2022-12-31 | 52.83% | ILA8.05 Million ≈ $21.57K |
ILA15.23 Million ≈ $40.83K |
-- |
About Plantarc Bio Ltd
PlantArc Bio Ltd. operates as an Ag-Bio company for the crop protection and yield enhancement. The company develops and operates a Direct-In-Plant gene discovery platform. It focuses on yield improvement, drought resistance, and herbicide and insects tolerance. The company was incorporated in 2014 and is based in Ra'anana, Israel.